4D Molecular Therapeutics, Inc.

FDMT

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001650648

SEC filings (opens in a new tab)

In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of FDMT: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	143	1	140	−2
Shares	57.3M	4.90M	58.2M	+5.80M (+11.1%)
Value	$1.20B	$102.8M	$629.2M	−$472.2M (−42.9%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to FDMT in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	4,868,789	$52.6M	0.00%
Norges Bank	524,711	$5.67M	0.00%
Armistice Capital, LLC	336,000	$3.63M	0.09%
Walleye Capital LLC	84,322	$911.5K	0.01%
SG Americas Securities, LLC	29,710	$321.0K	0.00%
Connor, Clark & Lunn Investment Management Ltd.	27,323	$295.4K	0.00%
DnB Asset Management AS	25,688	$277.7K	0.00%
Intech Investment Management LLC	24,761	$267.7K	0.00%
Two Sigma Advisers, LP	22,900	$247.5K	0.00%
Cubist Systematic Strategies, LLC	20,546	$222.1K	0.00%
Dark Forest Capital Management LP	18,717	$202.3K	0.03%
Nebula Research & Development LLC	16,787	$181.5K	0.02%
Point72 Asset Management, L.P.	15,341	$165.8K	0.00%
ProShare Advisors LLC	12,586	$136.1K	0.00%
Proficio Capital Partners LLC	10,000	$108.1K	0.01%
Values First Advisors, Inc.	5,315	$57.5K	0.03%
nVerses Capital, LLC	3,700	$40.0K	0.02%
Public Employees Retirement Association of Colorado	120	$1.00K	0.00%
Sterling Capital Management LLC	89	$962	0.00%
Ikarian Capital, LLC	39	$421	0.00%
Rothschild Investment LLC	35	$378	0.00%
Allspring Global Investments Holdings, LLC	27	$291	0.00%
Bessemer Group Inc	20	$0	0.00%

Sold out (25)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of FDMT in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Viking Global Investors LPSuperinvestorViking Global Investors	2,934,914	$61.6M
Opaleye Management Inc.	345,750	$7.26M
Sofinnova Investments, Inc.	271,155	$5.69M
Zimmer Partners, LP	138,800	$2.91M
Soleus Capital Management, L.P.	108,598	$2.28M
ExodusPoint Capital Management, LP	49,945	$1.05M
Verition Fund Management LLC	39,415	$827.3K
PDT Partners, LLC	39,356	$826.1K
Trexquant Investment LP	28,385	$595.8K
Principal Financial Group Inc	21,034	$441.5K
Bellevue Group AG	15,700	$329.5K
Sherbrooke Park Advisers LLC	15,578	$327.0K
HighVista Strategies LLC	15,532	$326.0K
Schonfeld Strategic Advisors LLC	14,273	$299.6K
Cantor Fitzgerald, L. P.	12,500	$262.4K
Brevan Howard Capital Management LP	11,079	$232.5K
Bridgefront Capital, LLC	10,171	$213.5K
Elmwood Wealth Management, Inc.	9,800	$205.7K
Capstone Investment Advisors, LLC	9,548	$200.4K
Group One Trading, L.P.	2,065	$43.3K
Pacer Advisors, Inc.	544	$11.4K
BFSG, LLC	500	$10.5K
Smartleaf Asset Management LLC	81	$1.70K
Allworth Financial LP	28	$404
Innealta Capital, LLC	4	$84

Not filed for Q3 2024 yet (1)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding FDMT in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	4,896,897	$102.8M